Opinion|Videos|August 13, 2024
Looking Ahead: Novel Therapies and Future Perspectives in the Treatment of CLL
The panel concludes its discussion with a look to the future of CLL treatment, focusing on emerging novel agents and exciting clinical research.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please share your insights on the growing significance of emerging novel agents in relapsed/refractory CLL.
- Which agents are you most excited about?
- How might these agents influence the future treatment landscape for CLL?
Advertisement
Related to this article
Pooled results from the phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials confirmed the efficacy of pirtobrutinib in treatment-naive CLL.
A post hoc analysis found similar safety outcomes for fixed-duration regimens containing acalabrutinib/venetoclax across age groups in treatment-naive CLL.
In an OncLive Peer Exchange, experts discussed the evolving treatment landscape in CLL, spanning frontline selection to emerging next-generation agents.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Darlifarnib Plus Cabozantinib Displays Early Signals of Safety and Efficacy in RCC
3
Five Under 5: Top Oncology Videos for the Week of 8/16
4
The OncFive: Top Oncology Articles for the Week of 8/16
5